Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Astra's shipments in 2024 are up 78%

1/29/25 ASTR

INARCTICA's revenues in 2024 to grow by 10.5%

1/29/25 AQUA

Moscow Exchange to launch weekend trading at the end of Q2 2025

1/28/25 MOEX

SPB Exchange from February 1 will start trading on weekends

1/28/25 SPBE

Samolot will repurchase the bonds for 84-92% of the par value

1/28/25 SMLT

Henderson's revenue in 2024 is up 24.2%

1/28/25 HNFG

Digital Habits Group started collecting applications for Pre-IPO participation

1/28/25 OTCI

On MOEX Start another Pre-IPO has been launched

1/28/25 MOEX

Lambumiz reported growth in production volumes

1/28/25 LMBZ

Whoosh's audience in 2024 has grown by 35%

1/28/25 WUSH